Skip to content

Relief Therapeutics Share Price Up 2,100%, COVID Drug Ready in “Few Months”

Nigel Frith Nigel Frith
Add as a preferred source on Google
Stock market or forex trading graph in graphic concept

Shares of Relief Therapeutics’ (SIX: RLF) closed the week 1,341% higher after its RLF-100 COVID-19 treatment showed an early potential in the second testing phase.

The chairman of the firm, Raghuram Selvaraju, believes that there is a “60%-70%” chance to get approval for the drug. 

“From an efficacy standpoint we need more data. I would say the probability at the moment stands at 60 to 70% that we will get the drug approved,” Selvaraju told Swiss newspaper The Market.

“The active pharmaceutical ingredient of aviptadil has been used for a lot of years in different indications. From a safety standpoint we are quite optimistic,” he added.

Relief holds a patent for Europe and the United States. It partnered with NeuroRx to run multicentre clinical trials. RLF-100 is targeting patients who are severely ill with COVID-19 infections, helping them to survive.

“I do not anticipate that we would need ten to 12 months for approval,” he concluded.

Relief Therapeutics’ share price gained on COVID-19 treatment August 2020

Relief Therapeutics’ share price closed 1,341% higher after trading over 2,100% in the green on Thursday. 

Nigel Frith
Nigel Frith
Team Member

Nigel has been in the regulated financial services industry for nearly a decade, has previously owned a financial brokerage and has written many times for sites relating to personal finance and trading.

Stay ahead of the markets

Sign up to our free Morning Markets email, every weekday before the open.